PCOS (Polycystic Ovarian Syndrome) is the most common endocrine disturbance affecting women between 15-30 years of age. It is estimated that 30% of all female infertility cases have 73% of suffering from PCOS. This study was aimed to evaluate the safety and efficacy of the trial drug Sanga Thiravagam (ST). Sanga Thiravagam (ST) was evaluated for ovulation inducing activity using Letrozole induced PCOS rat models, administered at the dose level of 5ml/kg with water, single dose daily for 4 consecutive oestrus cycles. Experimental animals divided into 4 groups. Group I was treated as control. Group II was treated with CMC solution along with Letrozole. Group III was treated with standard drug clomiphene and the Group IV was treated with trial drug. The trial drug ST 5ml/kg was given orally to the PCOS induced rats for 28 days. The vaginal smear collected everyday to find the changes of oestrous cycle. The biomarkers of ovarian function, oestrogen, FSH, and LH were analyzed to determine the fluctuations in sex steroid levels. There was significant decrease in ovary and reproductive organ weight in treated groups. There was significant decrease in the levels of hormones LH, FSH and increase in Estrogen level. Significant (P__ampersandsignlt;0.01) decrease in FSH, LH level of the treated group compared to standard. All the end points assessed were significantly improved after the treatment with ST and achieved levels close to standard drug clomiphene. The overall findings may be helpful to the population to treat female infertility. It is concluded that ST can be used more effectively in the treatment of female infertility and it was found to have a good potential to be a very good choice of therapy in the treatment of PCOS.